Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone

ObjectivesPerampanel is a selective and noncompetitive &agr;-amino-3-hydroxy-5-methylisoxazole propionic acid–type glutamate receptor antagonist that improves motor symptoms in animal models of Parkinson disease (PD). The aim of this study was to assess the efficacy and tolerability of perampanel in L-dopa–treated patients with moderately severe PD and motor fluctuations using an active comparator study design. MethodsThis was a prospective, randomized, double-blind, 3-arm, parallel-group, controlled study assessing the effects of perampanel (4 mg/d), placebo, or entacapone (200 mg with each dose of L-dopa) in 723 L-dopa–treated patients with PD with “OFF” problems. The primary outcome measure was the change from baseline in mean total daily OFF time based on diaries. Secondary end points included change from baseline in Unified Parkinson’s Disease Rating Scale part II while OFF, Unified Parkinson’s Disease Rating Scale part III while “ON,” and mean total daily ON time without dyskinesias or with nontroublesome dyskinesias. ResultsIn total, 480 patients (66.4%) completed the study, which was terminated early after negative results of 2 other large placebo-controlled studies became available. Perampanel was not superior to placebo on any efficacy end point, whereas entacapone was superior to placebo on the primary end point (P = 0.034) and most secondary outcomes. Perampanel was generally well tolerated. ConclusionsPerampanel (4 mg/d) was well tolerated but did not have a clinically significant effect in improving motor symptoms of L-dopa–treated patients with moderately advanced PD and motor fluctuations. These patients did respond to the active comparator, entacapone, confirming the validity of the findings despite the early termination of the study.